Targeted treatment for an 89-year-old woman with Stage IV HRD-positive ovarian cancer

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HRD-positive; germline BRCA2 pathogenic variant

Follow-up imaging showed a partial response, tumor markers improved, and she remained on treatment with better appetite and general condition at 7 months.

PubMed CentralRead more →

Stage I Invasive Ductal Carcinoma: Rachel's Patient Story

Patient Info: Rachel, Female | Stage I

Biomarkers: Genetic testing inconclusive; receptor status not reported

As of June 2026, Rachel had completed double mastectomy and chemotherapy for Stage IB breast cancer and remained on planned 10-year tamoxifen therapy, with ongoing joint/muscle pain, weight gain, and survivorship effects.

The Patient StoryRead more →

Stage IV Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage IV

Metastatic Site: Bones; liver; lymph nodes; stomach

As of June 2026, Bethany was living with Stage IV metastatic breast cancer and responding well to maintenance treatment, with scans described as phenomenal and disease areas shrinking or disappearing.

The Patient StoryRead more →

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient StoryRead more →

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient StoryRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient StoryRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Breast cancer treatment during pregnancy followed by postpartum targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

She achieved a near-complete response after 4 cycles of docetaxel and then continued systemic treatment after delivery.

PubMed CentralRead more →

I Lost My Wife To Metastatic Breast Cancer at 29 Years Old

Patient Info: Samantha, Female, Under 40 | Stage IV

Metastatic Site: rib/bone; lymph nodes; brain; liver

Samantha died from metastatic breast cancer in early January 2026 at age 29 after brain and liver progression, heart failure, and tumor lysis syndrome during her final hospitalization.

The Patient StoryRead more →

Stage I luminal A invasive ductal breast cancer with post-treatment cognitive symptoms

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER 100% positive; PR 95% positive; HER2 score 0 / HER2-negative; Ki-67 10%; P63 negative

As of April 2026, the case focused on survivorship after Stage I luminal A breast cancer treatment, with cognitive complaints after chemotherapy and improved MoCA and depression scores after 12 sessions of tDCS; brain metastases had been ruled out.

PubMed CentralRead more →

Stage II Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40 | Stage II

Biomarkers: Hormone receptor-positive; HER2-negative; BRCA inherited gene mutations negative

As of April 2026, Jenna had completed pregnancy-associated chemotherapy and double mastectomy for Stage II HR-positive, HER2-negative breast cancer with 1 involved lymph node, did not need radiation, and was on hormone therapy for 10 years.

Stage IV HR-Positive Breast Cancer: Joelle's Patient Story

Patient Info: Joelle, Female, Under 40 | Stage IV

Biomarkers: HR-positive / hormone-positive

Metastatic Site: Bone/hip; lymph nodes; other sites not specified

Living with Stage IV hormone-positive breast cancer on ongoing systemic therapy and monitoring, with tumor-marker checks every 3 months and scans every 6 months; no remission or NED status is stated.

The Patient StoryRead more →

Breast Cancer: Muriel's Patient Story

Patient Info: Muriel, Female

As of 16 April 2026, Muriel was in the antihormonal-therapy phase, living largely symptom-free after breast surgery and chemotherapy, and supporting other people with cancer as a peer counselor.

Stage IV Breast Cancer: Erica's Patient Story

Patient Info: Erica, Female, 40s | Stage IV

Biomarkers: Hormone-positive; HER2-negative

Metastatic Site: Bone — ribs, sternum, spine, femur/right hip, shoulder…

Living with stable Stage IV hormone-positive, HER2-negative metastatic breast cancer involving multiple bones, currently managed with monthly hormone-suppressant injections and monitoring.

The Patient StoryRead more →

Hormone receptor-positive high-grade encapsulated papillary breast carcinoma with limited invasion

Patient Info: Anonymized, Female, 40s

Biomarkers: ER/PR-positive, HER2-negative breast cancer; Ki-67 high in papillary/high-grade invasive areas; sentinel lymph nodes negative.

After mastectomy, sentinel-node evaluation, S-1, and endocrine therapy, she remained disease-free and in good health under regular follow-up.

PubMed CentralRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Stage IV ER-positive/HER2-negative breast cancer with synchronous gastric and bone metastases

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Gastric metastasis showed ER-positive, PR-negative, HER2 0 lobular breast cancer. Breast primary was ER/PR-positive, HER2-negative

Metastatic Site: bone; stomach/gastric

At 2-month follow-up, upper-GI symptoms had improved, anastrozole plus palbociclib was tolerated, and CT showed stable disease with persistent diffuse osseous metastases; no further follow-up was available.

PubMed CentralRead more →

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Sonja's Patient Story

Patient Info: Sonja Rideout, Female | Stage IV

Biomarkers: HER2-positive; Tempus testing later indicated immunotherapy as an option

Metastatic Site: Lungs; liver; bone: tailbone; thoracic lymph nodes

As of January 2026, Sonja was living with metastatic HER2-positive breast cancer after spread to lungs and liver, later tailbone and thoracic lymph nodes, and had moved to weekly carboplatin/gemcitabine plus monthly immunotherapy.

Breast cancer history with silicone lymphadenitis mimicking recurrence

Patient Info: Anonymized, Female, 70+

Workup of suspicious internal mammary and axillary lymph nodes found silicone-induced lymphadenitis from implant rupture, not breast cancer recurrence or metastasis.

PubMed CentralRead more →